United States District Court Northern Georgia recently order CRY to submit a legal response to various questions from the court by December 29. The court then gave Medafor had until January 12, 2010 to address the new CRY filing, and/or move to dismiss it.
The problem with CRY is this. They should get along with Medafor and just sell Hemostase like a banshee. There is very little cross selling. Acccordingly, CRY's case seems weak. If they would decided to sell Hemostase instead of fighting, CRY's revenues, gross profit, and stock prices would all do very well. Instead SGA has put his ego on the line via fighting a battle he is not likely to win, and may even lose.
CRY needs to grow revenues, via Hemostase. Then CRY stock goes up, possibly by a lot.